Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
Mes dernières consult.
Most popular
Report
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 1 287 B
EBIT 2018 220 B
Net income 2018 180 B
Finance 2018 391 B
Yield 2018 2,47%
Sales 2019 1 287 B
EBIT 2019 249 B
Net income 2019 194 B
Finance 2019 470 B
Yield 2019 2,58%
P/E ratio 2018 16,50
P/E ratio 2019 15,26
EV / Sales2018 2,04x
EV / Sales2019 1,98x
Capitalization 3 020 B
More Financials
Company
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic... 
Sector
Pharmaceuticals
Calendar
01/31Earnings Release
More about the company
Surperformance© ratings of Astellas Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC
11/16 ASTELLAS PHARMA : Findings from Astellas Pharma Yields New Findings on Medicinal..
11/16 SEATTLE GENETICS : and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in..
11/16 ASTELLAS PHARMA : Study Findings on Medicinal Chemistry Are Outlined in Reports ..
11/16 FINDINGS IN THE AREA OF PHARMACOLOGY : A novel highly...
11/16 ASTELLAS PHARMA : Study Findings from H.E. Burton et al Broaden Understanding of..
11/16 ASTELLAS PHARMA : New Central Nervous System Agents Findings from Astellas Pharm..
11/09 ASTELLAS PHARMA : Partners with CNBC for its Global Branding Campaign
11/09 SEATTLE GENETICS : and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in..
11/09 ASTELLAS PHARMA : and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Ved..
11/03 ASTELLAS PHARMA : and FibroGen Announce Positive Topline Results from First Japa..
More news
Sector news : Pharmaceuticals - NEC
11/18DJADRs End Higher; JA Solar, NetEase Trade Actively
11/17 British stocks fall back as Carillion crashes, Sky soars
11/17DJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
11/17DJROCHE : to Acquire U.S. Software Company Viewics
11/16 Europe approves GlaxoSmithKline's new triple lung drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/09 YOUR DAILY PHARMA SCOOP : Valeant Remains Risky, Novartis's Kisqali, Tesaro Tumb..
11/08 Seattle Genetics and Astellas launch early-stage study of enfortumab vedotin ..
11/02 CMS issues final list of therapies facing expiration of pass-through status f..
10/31 Astellas Pharma, Inc. ADR 2017 Q2 - Results - Earnings Call Slides
10/31 Astellas Pharma reports 1H results
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 553  JPY
Spread / Average Target 6,4%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-10.21%26 949
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550